Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
US9410139B2 · kind B2 · utility
2Cited by
5References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 12, 2008 |
| Grant date | Aug 9, 2016 |
| Priority date | — |
| Expiry date | Feb 1, 2029 |
Classification
- Technology area (CPC F)Mechanical Engineering; Lighting; Heating
- CPC primaryF16C19/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.